# Protara Therapeutics (TARA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/TARA
## Company Profile
- Ticker: TARA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Rare Disease
## Stock Data
- Close: 4.1 USD
- Market cap: 243926388.57999998 USD
- Last updated: 2026-08-06
## Business Overview
### Immunopotentiator Company
Protara Therapeutics develops TARA-002, a cell-based immunopotentiator derived from the same bacterial strain used in a historically approved immunotherapy.
### Lymphatic Malformations
The STARBORN program evaluates intralesional TARA-002 in pediatric and adult lymphatic malformations.
### Bladder Cancer
The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle invasive bladder cancer across BCG-unresponsive and BCG-naïve populations.
## Why The Stock Is Moving

As of Aug 6, 2026, TARA closed up 2.50% at $4.10. No new same-company headline was identified in the current news window.

## Future Catalysts

- Protara expects to complete enrollment in the BCG-unresponsive registrational cohort of ADVANCED-2 in the second half of 2026.
- The registrational ADVANCED-3 study in BCG-naïve patients is expected to begin in the second half of 2026.
- A BLA submission for TARA-002 in lymphatic malformations is planned for the second half of 2027.

## Drug Assets

- TARA-002

## Recent News
- 2026-05-20 12:00 EST — [Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-and-eha) — Source: Protara Therapeutics
- 2026-05-18 12:00 EST — [Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-for-lymphatic-malformations-on-tuesday-may-19-2026) — Source: Protara Therapeutics
- 2026-05-15 11:00 EST — [Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-in-the-fully-enrolled-bcg-naive-cohort-of-the-ongoing-phase-2-advanced-2-trial-of-tara-002-in-nmibc) — Source: Protara Therapeutics
- 2026-05-13 12:00 EST — [Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-first-quarter-2026-financial-results-and-provides-a-business-update) — Source: Protara Therapeutics
- 2026-04-27 20:05 EST — [Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-american-urological-association-annual-meeting) — Source: Protara Therapeutics